This invention provides a progesterone receptor antagonist of formula 1 having the structure ##STR1##

wherein T is O, S, or absent; R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or R₁ and R₂ are taken together form a ring and together contain —CH₂(CH₂)_nCH₂—, —CH₂CH₂CMe₂CH₂CH₂—, —O(CH₂)_pCH₂—, —O(CH₂)_qO—, —CH₂CH₂OCH₂CH₂—, or —CH₂CH₂NR₇CH₂CH₂—;

n=1-5; p=1-4; q=1-4;

R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or COR^A;

R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R₅ is hydrogen, alkyl, or substituted alkyl;

R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;

R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R₇ is hydrogen or alkyl, or a pharmaceutically acceptable salt thereof.